VR776

VR776 is a proprietary, inhaled formulation of an undisclosed centrally-acting drug developed by Vectura for the treatment of premature ejaculation. The product utilizes Vectura's Aspirair dry powder inhaler (DPI) and PowderHale technology to ensure efficient delivery and rapid systemic absorption through the lungs. Designed to work within the central nervous system to delay ejaculation, VR776 has demonstrated a rapid onset of action (within 15 minutes) and improved intravaginal ejaculatory latency time (IVELT) in Phase IIa clinical trials. It represents a novel approach to premature ejaculation therapy, offering a faster-acting alternative to conventional oral medications.